搜索筛选:
搜索耗时0.0803秒,为你在为你在102,285,761篇论文里面共找到 6 篇相符的论文内容
类      型:
[期刊论文] 作者:Li ZHONG,Chao-ming LI,Xiao-jiang HAO,Li-guang LOU, 来源:中国药理学报(英文版) 年份:2005
Aim: To investigate the apoptosis-inducing effect of cheliensisin A (GC-51), a novel styryl-lactone isolated from Goniothalamus cheliensis, on human promyelocyt...
[期刊论文] 作者:Xiang-ling Chen,Peng Liu,Wei-liang Zhu,Li-guang Lou, 来源:中国药理学报(英文版) 年份:2021
Hsp90 is a potential therapeutic target for tumor,as it maintains the stability of a variety of proteins related to tumor development and progression.Autophagy...
[期刊论文] 作者:Li-xian WU,Ying WU,Rui-jia CHEN,Yang LIU,Li-sen HUANG,Li-guang LOU,Zhi-hong ZHENG, 来源:中国药理学报(英文版) 年份:2014
[期刊论文] 作者:Chang-yong Yang,Lei Wang,Xing Sun,Mi Tang,Hai-tian Quan,Lian-shan Zhang,Li-guang Lou,Shao-hua Gou, 来源:中国药理学报(英文版) 年份:2019
Emerging evidence demonstrates that a c-Met antibody-drug conjugate (ADC) has superior efficacy and safety profiles compared with those of currently available s...
[期刊论文] 作者:Ming-zhao Gao,Hong-bin Wang,Xiang-ling Chen,Wen-ting Cao,Li Fu,Yun Li,Hai-tian Quan,Cheng-ying Xie,Li-guang Lou, 来源:中国药理学报(英文版) 年份:2019
BRAF and MEK inhibitors have shown remarkable clinical efficacy in BRAF-mutant melanoma;however,most patients develop resistance,which limits the clinical benef...
[期刊论文] 作者:,Fei-fei DU,Su-ping ZHANG,Chengying XIE,Na-ting ZHANG,Olajide E OLALEYE,Feng-qing WANG,Fang XU,Li-guang LOU, 来源:中国药理学报(英文版) 年份:2018
Anlotinib is a new oral tyrosine kinase inhibitor; this study was designed to characterize its pharmacokinetics and disposition. Anlotinib was evaluated in rats...
相关搜索: